GSK responds to O’Neill Review's antibiotic resistance report
GSK, a major pharmaceutical company, is one of the few in the health industry that is still actively researching and developing antibiotics. The company’s antibiotic legacy is more than 40 years strong, and in the past 10 years, GSK has invested approximately $1 billion into researching and developing the antibiotics industry.
“It is essential that we find new ways to increase antibiotics (research and development) and create a future pipeline of new treatments,” the statement said. “Antibiotic resistance is a hugely complex problem with potentially devastating consequences for public health. As one of the few companies still conducting research in this area, we welcome today’s report."
The GSK statement also noted that creating new antibiotics is a scientifically and financially challenging endeavor.
“We are very encouraged by the ideas it sets out to modernise the economic model to encourage investment in research and ensure reasonable returns for successful innovation while discouraging unnecessary use of new antibiotics,” the statement said. “We look forward to working closely with the AMR Review Team and others to take these ideas forward.”